BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36197572)

  • 1. Preoperative endogenous testosterone density predicts disease progression from localized impalpable prostate cancer presenting with PSA levels elevated up to 10 ng/mL.
    Porcaro AB; Bianchi A; Mazzucato G; Gallina S; Serafin E; Tafuri A; Cerrato C; Panunzio A; Vidiri S; D'Aietti D; Orlando R; Brusa D; Brunelli M; Siracusano S; Cerruto MA; Antonelli A
    Int Urol Nephrol; 2023 Jan; 55(1):85-92. PubMed ID: 36197572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Influence of Endogenous Testosterone Density on Unfavorable Disease and Tumor Load at Final Pathology in Intermediate-Risk Prostate Cancer: Results in 338 Patients Treated with Radical Prostatectomy and Extended Pelvic Lymph Node Dissection.
    Porcaro AB; Panunzio A; Tafuri A; Cerrato C; Gallina S; Bianchi A; Rizzetto R; Amigoni N; Gozzo A; Serafin E; Cianflone F; Migliorini F; Vidiri S; Di Filippo G; Novella G; Brunelli M; Shakir A; Pagliarulo V; Cerruto MA; Siracusano S; Antonelli A
    Urol Int; 2022; 106(9):928-939. PubMed ID: 35081537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative endogenous total testosterone predicts prostate cancer progression: results in 580 consecutive patients treated with robot assisted radical prostatectomy for clinically localized disease.
    Porcaro AB; Panunzio A; Serafin E; Bianchi A; Gallina S; Mazzucato G; Vidiri S; D'Aietti D; Orlando R; Ditonno F; Montanaro F; Marafioti Patuzzo G; Bailelli A; Artoni F; Zecchini Antoniolli S; Rizzetto R; Brunelli M; Siracusano S; Cerruto MA; Tafuri A; Antonelli A
    Int Urol Nephrol; 2023 May; 55(5):1139-1148. PubMed ID: 36943597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous testosterone density is an independent predictor of pelvic lymph node invasion in high-risk prostate cancer: results in 201 consecutive patients treated with radical prostatectomy and extended pelvic lymph node dissection.
    Porcaro AB; Tafuri A; Panunzio A; Mazzucato G; Cerrato C; Gallina S; Bianchi A; Rizzetto R; Amigoni N; Serafin E; Cianflone F; Orlando R; Gentile I; Migliorini F; Zecchini Antoniolli S; Di Filippo G; Brunelli M; Pagliarulo V; Cerruto MA; Antonelli A
    Int Urol Nephrol; 2022 Mar; 54(3):541-550. PubMed ID: 35044553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive independent association between preoperative endogenous testosterone density and tumor load density in surgical specimen of patients undergoing radical prostatectomy.
    Porcaro AB; Bianchi A; Gallina S; Serafin E; Mazzucato G; Panunzio A; Tafuri A; Montanaro F; Marafioti Patuzzo G; Baielli A; Artoni F; Vidiri S; Cianflone F; D'Aietti D; Brunelli M; Siracusano S; Cerruto MA; Antonelli A
    Urologia; 2024 Feb; 91(1):76-84. PubMed ID: 37526101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous testosterone density as ratio of endogenous testosterone levels on prostate volume predicts tumor upgrading in low-risk prostate cancer.
    Porcaro AB; Gallina S; Bianchi A; Cerrato C; Tafuri A; Rizzetto R; Amigoni N; Orlando R; Serafin E; Gozzo A; Migliorini F; Antoniolli SZ; Lacola V; De Marco V; Brunelli M; Cerruto MA; Siracusano S; Antonelli A
    Int Urol Nephrol; 2021 Dec; 53(12):2505-2515. PubMed ID: 34677784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous testosterone density predicts unfavorable disease at final pathology in intermediate risk prostate cancer.
    Porcaro AB; Tafuri A; Panunzio A; Rizzetto R; Amigoni N; Cerrato C; Shakir A; Gallina S; Bianchi A; Cianflone F; Serafin E; Gozzo A; Di Filippo G; Migliorini F; Novella G; Brunelli M; Cerruto MA; Antonelli A
    Int Urol Nephrol; 2021 Dec; 53(12):2517-2526. PubMed ID: 34580803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of endogenous testosterone density on prostate cancer progression in patients with very favorable low and intermediate risk treated with radical prostatectomy.
    Porcaro AB; Tafuri A; Panunzio A; Cerrato C; Bianchi A; Gallina S; Vidiri S; D'Aietti D; Serafin E; Mazzucato G; Princiotta A; Brusa D; Brunelli M; Pagliarulo V; Cerruto MA; Antonelli A
    Asian J Androl; 2023 Jan; 25(5):556-63. PubMed ID: 36629157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normal preoperative endogenous testosterone levels predict prostate cancer progression in elderly patients after radical prostatectomy.
    Porcaro AB; Panunzio A; Bianchi A; Cerrato C; Gallina S; Serafin E; Mazzucato G; Vidiri S; D'Aietti D; Orlando R; Brusa D; Brunelli M; Siracusano S; Pagliarulo V; Cerruto MA; Tafuri A; Antonelli A
    Ther Adv Urol; 2023; 15():17562872231154150. PubMed ID: 36846295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of palpable prostate tumors on disease progression after robot-assisted radical prostatectomy: a single-center experience.
    Porcaro AB; Gallina S; Bianchi A; Tafuri A; Serafin E; Panunzio A; Mazzucato G; Orlando R; Ditonno F; Ornaghi PI; Rizzetto R; Cerrato C; De Marco V; Brunelli M; Siracusano S; Cerruto MA; Antonelli A
    J Robot Surg; 2023 Oct; 17(5):2471-2477. PubMed ID: 37486540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total testosterone density predicts high tumor load and disease reclassification of prostate cancer: results in 144 low-risk patients who underwent radical prostatectomy.
    Porcaro AB; Tafuri A; Sebben M; Processali T; Pirozzi M; Shakir A; Amigoni N; Rizzetto R; Brunelli M; Migliorini F; Siracusano S; Artibani W
    Int Urol Nephrol; 2019 Dec; 51(12):2169-2180. PubMed ID: 31444696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results.
    Neuzillet Y; Raynaud JP; Dreyfus JF; Radulescu C; Rouanne M; Schneider M; Krish S; Rouprêt M; Drouin SJ; Comperat E; Galiano M; Cathelineau X; Validire P; Molinié V; Fiet J; Giton F; Lebret T; Botto H
    Horm Cancer; 2019 Feb; 10(1):36-44. PubMed ID: 30293206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The preoperative serum ratio of total prostate specific antigen (PSA) to free testosterone (FT), PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy.
    Porcaro AB; Caruso B; Terrin A; De Luyk N; Cacciamani G; Corsi P; Inverardi D; De Marchi D; Baldassarre R; Cerruto M; Ghimenton C; Brunelli M; Zecchini Antoniolli S; Petrozziello A; Artibani W
    Arch Ital Urol Androl; 2016 Mar; 88(1):17-22. PubMed ID: 27072171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy.
    Bravi CA; Droghetti M; Fossati N; Gandaglia G; Suardi N; Mazzone E; Cucchiara V; Scuderi S; Barletta F; Schiavina R; Osmonov D; Juenemann KP; Boeri L; Karnes RJ; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Grubmüller B; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
    Eur Urol Oncol; 2022 Jun; 5(3):285-295. PubMed ID: 34176768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy.
    Lane BR; Stephenson AJ; Magi-Galluzzi C; Lakin MM; Klein EA
    Urology; 2008 Dec; 72(6):1240-5. PubMed ID: 18692874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
    Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
    Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
    Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
    Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating preoperative testosterone level predicts unfavourable disease at radical prostatectomy in men with International Society of Urological Pathology Grade Group 1 prostate cancer diagnosed with systematic biopsies.
    Ferro M; Lucarelli G; de Cobelli O; Vartolomei MD; Damiano R; Cantiello F; Crocerossa F; Perdonà S; Del Prete P; Cordima G; Musi G; Del Giudice F; Busetto GM; Chung BI; Porreca A; Ditonno P; Battaglia M; Terracciano D
    World J Urol; 2021 Jun; 39(6):1861-1867. PubMed ID: 32683462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8-10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer.
    Dai B; Qu Y; Kong Y; Ye D; Yao X; Zhang S; Wang C; Zhang H; Yang W
    BJU Int; 2012 Dec; 110(11 Pt B):E667-72. PubMed ID: 22974446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.